Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Replimune Group Presents Final First-in-Human Data for RP2 Oncolytic ...
Replimune gets third chance at US approval for skin cancer drug | Reuters
Replimune takes third swing at cancer drug approval following ...
Replimune Group, Inc.: Replimune Announces Planned RP1 BLA Resubmission ...
FinancialContent - Replimune Announces Planned RP1 BLA Resubmission ...
FDA again spurns Replimune melanoma drug | BioPharma Dive
Replimune Aktie: 218 Prozent in 30 Tagen
Replimune Stock Plunged 42% Today – Here’s Why
Replimune Stock: Multiple Shots On Goal But A High Risk Binary ...
Replimune Aktie: FDA signalisiert Priorität für RP1
Replimune Group, Inc. (REPL) Stock Historical Price Data, Closing Price ...
Replimune Aktie: 182 Prozent Anstieg in 30 Tagen
Replimune Aktie: RP1-Einreichung am 11. Juni erwartet
BioNTech sichert Milliarden-Deal, Replimune fiebert ASCO entgegen
FDA Rejects Replimune Melanoma Therapy, Citing Data Concerns - Pharma ...
Replimune Announces Pricing of Upsized Public Offering By Investing.com ...
HC Wainwright Raises Earnings Estimates for Replimune Group - American ...
Replimune receives CRL on BLA for RP1 for advanced melanoma | pharmaphorum
Replimune rocked by CRL for lead candidate | The Pharmaletter
Replimune layoffs: Woburn biotech cuts 224 jobs after FDA rejection ...
Replimune stock collapses 64% following FDA rejection | REPL - TheStreet
Replimune (REPL) Stock Falls 19% After FDA Rejects RP1 Melanoma Drug ...
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy ...
Replimune Group Presents Promising Clinical Data at J.P. Morgan Conference
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL ...
FDA's Makary defends Replimune drug rejection amid backlash
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair’
Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock ...
The Replimune Saga Reveals a Bad Look for Medical Affairs
Replimune Announces RP2 Development Program Advances First Patients ...
Replimune Faces Pivotal FDA Decision Amid Insider Transaction
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the ...
Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for ...
Replimune Saved My Father - WSJ
Replimune says it’s waiting for FDA on a path forward for rejected ...
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits ...
Replimune Shares Surge Ahead of Key FDA Decision Date - Stocks Today
Why Replimune Stock Was Soaring Today | The Motley Fool
Replimune Faces Pivotal FDA Verdict on Skin Cancer Therapy | NewsCase
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes ...
FDA Rejects Replimune Melanoma Drug, Citing Insufficient Evidence for ...
Why Replimune Stock Plummeted by Almost 40% Today | The Motley Fool
Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA ...
Replimune cuts will leave over 200 jobless in Massachusetts - BioSpace
The Replimune Complete Response Letter: A Case Study in Regulatory ...
Replimune Stock at a Crossroads: Insider Sales and Regulatory Hurdles ...
Replimune Group Stock Soars 85.33% Amid Lawsuit Reassessment
6 Reasons Why Replimune Offers Huge Growth Potential!
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug - BioSpace
Replimune on LinkedIn: Earlier today we announced the addition of Chris ...
Replimune sees layoffs as FDA snubs cancer drug (REPL:NASDAQ) | Seeking ...
FDA Issues CRL to Replimune for RP1 Biologics License Application for ...
Replimune Investors Await Critical Regulatory and Financial Milestones ...
FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With ...
Replimune Group, Inc. (REPL) Stock: Soars 120% After FDA Accepts RP1 ...
Replimune Group, Inc. (REPL): Business Model Canvas – DCFmodeling.com
Replimune Scraps RP2 and RP3 Clinical Programs After Phase 2 Miss ...
Replimune Group Faces Lawsuit After FDA Denies Drug Approval ...
Replimune gets FDA complete response letter for RP1 | REPL Stock News
Biotech Firm Replimune Gains Momentum with Key FDA Submission ...
Replimune shares surge after FDA accepts Melanoma drug resubmission ...
Here's Why Replimune Group (REPL) Stock Is Up Over…
Replimune FDA Meeting Update: RP1 Melanoma Drug Path Unclear | REPL ...
Why Did Replimune Group Stock Soar 9.84% Ahead of FDA Decision?
Replimune Faces Mounting Legal Challenges Following Drug Rejection ...
Replimune on LinkedIn: Replimune's CEO discusses last week's PD-1 ...
© 2025 Replimune Group Inc. © 2026 Replimune Group Inc. 6 Anti - PD - 1 ...
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application
Replimune gains as FDA to discuss path for rejected skin cancer drug
Replimune Shares Surge on Regulatory Breakthrough
Replimune plunges after FDA rejects skin cancer drug again
Transforming Cancer Treatment | Replimune
Replimune logo in transparent PNG and vectorized SVG formats
Culture and Careers | Replimune
Medical Professionals | Replimune
Science | Replimune
Exclusive | How Replimune’s Drug Got Third Chance After White House ...
REPL Q4 2026 Earnings Report on 6/4/2026
A Welcome FDA Reversal on a Melanoma Drug - WSJ
REPL Q1 2026 Earnings Report on 8/7/2025
Ambarella Drops 20% After AI Beat, $800 Million Hanwha Contract
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug ...
@BiotechTV @Replimune @US_FDA LMFAO, that guy is a tool. $IOVA already ...
Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See ...
FDA Commissioner Makary defends agency's decision on Replimune's drug ...
FDA Rejects Replimune's Melanoma Drug Again — and the Company May Walk ...
Replimune's RP1 Shows 44% Response in Acral Melanoma | REPL Stock News
Replimune's JPM Setup: A 22.5% Drop Before the April PDUFA Test
Researchers behind Replimune’s melanoma study offer a rare protest of ...
FDA Delays Approval of Replimune’s Melanoma Therapy Despite Promising ...
FDA hands another rejection to Replimune's melanoma therapy | pharmaphorum
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL ...
Replimune's Advanced Skin Cancer Drug RP1 Faces FDA Rejection for ...
Replimune's Regulatory and Legal Turbulence: A Cautionary Tale for ...
FDA Accepts Replimune's BLA for RP1 + Nivolumab in Melanoma | OncoDaily ...
Replimune's Pivotal Year: All Eyes on 2026 FDA Decision - Stocks Today
RFK Jr. says no hand in rejecting Replimune's lead asset
Replimune's Inducement Grants: Attracting Talent, Boosting Motivation ...
Replimune: FDA accepts RP1 BLA; PDUFA set for Apr 10, 2026 | REPL 8-K ...
Unraveling Replimune’s 8.57% Surge: A Mystery Without Fundamental Clues
Replimune’s Turmoil: What Comes Next?
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma ...
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment ...
Replimune's RP1 Gains Breakthrough Status and Files FDA Application for ...
